Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center

References

• Harigai M, Mochida S, Mimura T, Koike T, Miyasaka N. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Mod Rheumatol. 2014;24(1):1–7.
   PubMed Web of Science ®Google Scholar
• Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42(7):627–36.
   PubMed Web of Science ®Google Scholar
• JSH Guidelines for the Management of Hepatitis B Virus Infection 2020 (Version 3.2) (in Japanese). The Japan Society of Hepatology. Japanese. Available from: https://www.jsh.or.jp/files/uploads/HBV_GL_ver3.2_20200926.pdf
   Google Scholar
• Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant Lymphoma. Int J Hematol. 2009;90(1):13–23.
   PubMed Web of Science ®Google Scholar
• Mochida S, Nakao M, Nakayama N, Uchida Y, Nagoshi S, Ido A, et al. Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies. J Gastroenterol. 2016;51(10):999–1010.
   PubMed Web of Science ®Google Scholar
• Ito S. Management of hepatitis in patients treated with biological disease-modifying antirheumatic drugs (in Japanese). Clin Rheumatol Rel Res. 2016;28:311–6.
   Google Scholar
• Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, et al. Incidence of Hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis. 2017;76(6):1051–6.
   PubMed Web of Science ®Google Scholar
• Fujita M, Sugiyama M, Sato Y, Nagashima K, Takahashi S, Mizokami M, et al. Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan. J Viral Hepat. 2018;25(11):1312–20.
   PubMed Web of Science ®Google Scholar
• Kato M, Atsumi T, Koike T, Odani T, Fujieda Y, Otomo K, et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. J Rheumatol. 2011;38(10):2209–14.
   PubMed Web of Science ®Google Scholar
• Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, et al. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Res Ther. 2019;21(1):255.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Fukae J, Fukaya S, Sawamukai N, Isobe M, Matsuhashi M, et al. Incidence and risk factors for inducing the reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2019;22(4):574–82.
   PubMed Web of Science ®Google Scholar
• Solay AH, Acar A, Eser F, Kuşcu F, Tütüncü EE, Kul G, et al. Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity. Turk J Gastroenterol. 2018;29(5):561–5.
   PubMed Web of Science ®Google Scholar
• Chen YM, Chen HH, Huang WN, Chen YH, Hsieh TY, Yang SS, et al. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: a long-term, real-world observation. Int J Rheum Dis. 2019;22:1145–51.
   PubMed Web of Science ®Google Scholar
• Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344(1):68–9.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, Lam WY, Mo FKF, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605–11.
   PubMed Web of Science ®Google Scholar
• Umemura T, Tanaka E, Kiyosawa K, Kumada H, 16. Japan de novo Hepatitis B Research Group. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47(5):e52.
   PubMed Web of Science ®Google Scholar
• Ito S, Ohkoshi S, Ofuchi Y, Hasegawa H, Nakano M, Gejyo F. A case of systemic sclerosis who developed hepatitis B with the tapering of prednisolone (in Japanese). Rheumatology. 2000;21:208–12.
   Google Scholar
• Matsumoto T, Marusawa H, Dogaki M, Suginoshita Y, Inokuma T. Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection . Liver Int. 2010;30(8):1241–2.
   PubMed Web of Science ®Google Scholar
• Kobashi H, Toshimori J, Koyama Y, Fujii S, Takeuchi M. A study of hepatitis B virus (HBV) reactivation associated with immunosuppression/chemotherapy at our hospital, 2015-2017 (in Japanese). J Japanese Red Cross Okayama Hospital. 2018;29:26–33.
   Google Scholar
• Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2016 May;19(5):470–5.
   PubMed Web of Science ®Google Scholar
• Kanbori M, Suzuka M, Yajima T, Kishino E, Morishige R, Momohara S, et al. Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2018;28(1):66–75.
   PubMed Web of Science ®Google Scholar
• Post market surveillance of certolizumab pegol (2013 March to 2019 Mach, 9th regular safety report, in Japanese).
   Google Scholar
• Germanidis G, Hytiroglou P, Zakalka M, Settas L. Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol. 2012;56(6):1420–1.
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Vassilopoulos D, Repa A, Boumpas DT, Sidiropoulos P. Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. Rheumatology (Oxford). 2014;53(1):195–6.
   PubMed Web of Science ®Google Scholar
• Talotta R, Atzeni F, Puttini PS. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report. BMC Pharmacol Toxicol. 2016;17(1):17.
   PubMedGoogle Scholar
• Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, et al. Risk of HBV Reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133(2):137–46.
   PubMed Web of Science ®Google Scholar
• Chen YM, Huan WN, Wu YD, Lin CT, Chen YH, Chen DY, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018;77(5):780–2.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Inc. Smyraf® 50 mg, and 100 mg tablets summary of product characteristics. 2020.
   Google Scholar
• Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B Virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–9.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int. 2016;10(1):1–98.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.
   PubMed Web of Science ®Google Scholar
• Myint A, Tong MJ, Beaven SW. Reactivation of hepatitis B virus: a review of clinical guidelines. Clin Liver Dis. 2020;15(4):162–7.
   Google Scholar
• Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–309.
   PubMed Web of Science ®Google Scholar
• Moghoofei M, Mostafaei S, Ashraf-Ganjouei A, Kavosi H, Mahmoudi M. HBV reactivation in rheumatic diseases patients under therapy: a meta-analysis. Microb Pathog. 2018;114:436–43.
   PubMed Web of Science ®Google Scholar
• Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases. Ther Adv Muscuroskel Dis. 2020;12:1–19.
   Web of Science ®Google Scholar
• Takahashi H, Ikeda M, Kumada T, Osaki Y, Kondo S, Kusumoto S, et al. Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. Hepatol Res. 2015;45(12):1220–7.
   PubMed Web of Science ®Google Scholar
• Yuki M, Ishida H, Ohkubo K, Kawashima Matsunaga HH. A. Analysis of hepatitis B virus reactivation in Fukuoka University Hospital (in Japanese). Rinsho Byori. 2016;64(6):625–30.
   PubMedGoogle Scholar
• Yang C, Qin B, Yuan Z, Chen L, Zhou HY. Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation. Ann Hepatol. 2016;15(4):501–11.
   PubMed Web of Science ®Google Scholar
• Hui C, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59–68.
   PubMed Web of Science ®Google Scholar
• Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001;44(2):339–42.
   PubMedGoogle Scholar
• Kobayashi D, Ito S, Takai C, Abe A, Ishikawa H, Murasawa A, et al. Type E hepatitis in rheumatoid arthritis patients. Mod Rheumatol Case Rep. 2017;1(2):30–4.
   Google Scholar
• Ito S, How to use antirheumatic drugs in rheumatoid arthritis patients with liver dysfunction. In: Sano H, Azuma N, editors. Guidebook for antirheumatic drugs in clinical practice (in Japanese). Osaka (Japan): Fujimedeical Publishing; 2019. p. 87–92.
   Google Scholar